Vol. 5 (12) pp. 1537-1544 DOI: 10.21474/IJAR01/6117

DISCUSSION ABOUT TREATMENT OF ULCERATIVE COLITIS.

, , , , , and
18 Downloads 162 Views
Crossref

Download Full Paper (PDF)

How to Cite This Article

Lujain alfattany, Mohanned khder sharif, Emad Mokhtar Salem Mabkhot, Sumaiah alfaleh, Zainab Kefah AlSenan, Marzouq Muyid R Almansouri and Zainah Saleh Salman Ba-Saleh. (2017); DISCUSSION ABOUT TREATMENT OF ULCERATIVE COLITIS., International Journal of Advanced Research (IJAR), 5 (12), 1537-1544, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/6117

Corresponding Author

Lujain alfattany

Article Analytics

References

  1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.?Abstract
  2. Mackalski BA, Bernstein CN. New diagnostic imaging tools for inflammatory bowel disease. Gut. 2006;55:733-741.?Abstract
  3. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.
  4. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;2:CD000543.
  5. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.?Abstract
  6. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97:1398-1407.?Abstract
  7. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.?Abstract
  8. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med. 1996;124:204-211.?Abstract
  9. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001;49:783-789.?Abstract
  10. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther. 2005;21:1111-1119.?Abstract
  11. Marteau P, Crand J, Foucault M, Rambaud JC. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut. 1998;42:195-199.?Abstract
  12. Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000;95:1749-1754.?Abstract
  13. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867-1871.?Abstract
  14. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998;4:79-83.?Abstract
  15. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263-1276.?Abstract
  16. Piodi LP, Ulivieri FM, Cermesoni L, Cesana BM. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol. 2004;39:154-157.?Abstract
  17. Frieri G, Pimpo MT, Palumbo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther. 1999;13:1413-1417.?Abstract
  18. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54:960-965.?Abstract
  19. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536-539.?Abstract
  20. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004;126:1733-1739.?Abstract
  21. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.?Abstract
  22. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.?Abstract
  23. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol. 1999;94:1733-1742.?Abstract
  24. Bresci G, Parisi G, Bertoni M, Capria A. Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. Dig Liver Dis. 2002;34:419-423.?Abstract
  25. Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272-286.?Abstract
  26. Saibeni S, Cortinovis I, Beretta L, et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology. 2005;52:509-515.?Abstract
  27. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.?Abstract
  28. Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory boweld disease. Aliment Phamacol Ther. 2003;18(suppl2):15-21.
  29. Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784-2788.
  30. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145-153.
  31. Rubin DT, LoSavio A, Huo D, Yadron N, Hanauer SB. Use of 5-ASA is associated with decreased risk of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. In press.
  32. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.?Abstract
  33. Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005;100:1354-1356.
  34. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11:421-427.?Abstract
  35. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. Combined data from two pivotal, randomized, placebo-controlled, phase-III studies show that SPD476, a novel mesalamine formulation given once or twice daily is effective for the induction of remission of mild-to-moderate ulcerative colitis. Gastroenterology. 2006;130:A813.
  36. Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001;7:237-242.?Abstract
  37. Lamet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis. 2005;11:625-630.?Abstract
  38. Aumais G, Lefebvre M, Massicotte J, et al. Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis. Drugs R D. 2005;6:41-46.?Abstract
  39. Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther. 1999;13:381-388.?Abstract
  40. Lichtenstein G. SPD476 is a novel, once-daily, high-dose, effective and well tolerated 5ASA formulation for the induction of remission of mild-to-moderate ulcerative colitis: a phase III study. Am J Gastroenterol. 2005;100:A21.
  41. Kamm M. Comparison of the efficacy and safety of SPD476, a novel, once-daily, high dose formulation of mesalamine, and Asacol with placebo for the induction of remission of mild-moderate ulcerative colitis: a phase III study. Am J Gastroenterol. 2005;100:A22.
  42. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.?Abstract
  43. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.?Abstract
  44. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.?Abstract
  45. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience. Gastroenterology. 2004;126:19-31.?Abstract
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.